Atossa Therapeutics, Inc. (ATOS): Operating Cash Flow
-$29.76M
Year ended 2025-12-31
-$35.77M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$29.76M | n/m | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | -$21.03M | n/m | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | -$20.94M | n/m | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | -$20.76M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$16.47M | n/m | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | -$11.57M | n/m | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | -$9.13M | n/m | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | -$8.96M | n/m | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | -$6.59M | n/m | 2019-03-28, From 2017-01-01 |
| 2016-12-31 | -$5.37M | n/m | 2018-03-08, From 2016-01-01 |
| 2015-12-31 | -$13.95M | n/m | 2017-03-21, From 2015-01-01 |
| 2014-12-31 | -$10.56M | n/a | 2016-03-30, From 2014-01-01 |
| No annual figure between 2012-12-31 and 2014-12-31. | |||
| 2012-12-31 | -$3.90M | n/m | 2013-03-28, From 2012-01-01 |
| 2011-12-31 | -$3.49M | n/a | 2013-03-28, From 2011-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | -$29.76M | n/m |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | -$10.57M | n/m |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | -$17.63M | n/m |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | -$66.44M | n/m |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | -$31.32M | n/m |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | -$30.97M | n/m |
| Medicinova Inc (MNOV) | 2025-12-31 | -$9.81M | n/m |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | -$10.74M | n/m |
| NextCure, Inc. (NXTC) | 2025-12-31 | -$49.61M | n/m |
Compare ATOS, AKTX, VRCA, VTGN side by side · Screen every company in Pharmaceutical Preparations ↗